Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 - Concepedia

Concepedia

Publication | Open Access

Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

DOI Full Paper Access

984

Citations

12

References

2014

Year

Edith A. Perez, Edward H. Romond, Vera J. Suman, Jong‐Hyeon Jeong, George W. Sledge, Charles E. Geyer, Silvana Martino, Priya Rastogi, Julie R. Gralow, Sandra M. Swain,

Journal of Clinical Oncology

Abstract

The addition of trastuzumab to paclitaxel after doxorubicin and cyclophosphamide in early-stage HER2-positive breast cancer results in a substantial and durable improvement in survival as a result of a sustained marked reduction in cancer recurrence.

References

	Year	Citations

Page 1